A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Borate, Uma, Pollyea, Daniel A., Brunner, Andrew M., Roncolato, Fernando, Garcia, Jacqueline S., Filshie, Robin, Odenike, Olatoyosi, Watson, Anne Marie, Krishnadasan, Ravitharan, Bajel, Ashish, Naqvi, Kiran, Zha, Jiuhong, Cheng, Wei‐Han, Zhou, Ying, Hoffman, David, Harb, Jason G., Potluri, Jalaja, Garcia‐Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100228/
https://www.ncbi.nlm.nih.gov/pubmed/36309981
http://dx.doi.org/10.1002/ajh.26771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100228/
https://www.ncbi.nlm.nih.gov/pubmed/36309981
http://dx.doi.org/10.1002/ajh.26771

Ejemplares similares